Adebrelimab Plus Chemoradiotherapy Followed by Adebrelimab Maintenance in Limited-Stage SCLC

This is a single-arm, open-label, single-center phase II trial that will enroll 30 patients with limited-stage small-cell lung cancer to evaluate the safety and efficacy of adebrelimab combined with chemoradiotherapy followed by adebrelimab maintenance.

NCT Number	NCT07200154
Lead Sponsor	Peking University Cancer Hospital & Institute
Conditions	Limited-stage Small-cell Lung Cancer, Concurrent Chemoradiation Therapy
Enrollment	30 participants
Start Date	2025-09-30
Primary Completion	2028-03-30 (estimated)
Study Completion	2028-09 (estimated)
Updated on ClinicalTrials.gov	2025-09-30